Glimepiride is a second-generation sulfonylurea that received FDA approval in 1995 to use for the improvement of glycemic control in adults with type 2 diabetes mellitus.

Glimepiride is sometimes referred to as a third-generation sulfonylurea as it has a better safety profile and has a prolonged duration of action of up to 24 hours.